Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 16;5(1):48-63.
doi: 10.3390/cancers5010048.

Gastric cancer: current status of diagnosis and treatment

Tsunehiro Takahashi  1 , Yoshiro Saikawa, Yuko Kitagawa
Affiliations

Gastric cancer: current status of diagnosis and treatment

Tsunehiro Takahashi et al. Cancers (Basel). .

Abstract

Gastric cancer is the second leading cause of death from malignant disease worldwide and most frequently discovered in advanced stages. Because curative surgery is regarded as the only option for cure, early detection of resectable gastric cancer is extremely important for good patient outcomes. Therefore, noninvasive diagnostic modalities such as evolutionary endoscopy and positron emission tomography are utilized as screening tools for gastric cancer. To date, early gastric cancer is being treated using minimally invasive methods such as endoscopic treatment and laparoscopic surgery, while in advanced cancer it is necessary to consider multimodality treatment including chemotherapy, radiotherapy, and surgery. Because of the results of large clinical trials, surgery with extended lymphadenectomy could not be recommended as a standard therapy for advanced gastric cancer. Recent clinical trials had shown survival benefits of adjuvant chemotherapy after curative resection compared with surgery alone. In addition, recent advances of molecular targeted agents would play an important role as one of the modalities for advanced gastric cancer. In this review, we summarize the current status of diagnostic technology and treatment for gastric cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Median survival time of phase III trials of chemotherapy for unresectable gastric cancer were summarized.
See this image and copyright information in PMC

References

    1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 2010;127:2893–2917. - PubMed
    1. Ezoe Y., Muto M., Uedo N., Doyama H., Yao K., Oda I., Kaneko K., Kawahara Y., Yokoi C., Sugiura Y., et al. Magnifying narrowband imaging is more accurate than conventional white-lite imaging in diagnosis of gastric mucosal cancer. Gastroenterology. 2011;141:2017–2025. - PubMed
    1. Nagahama T., Yao K., Maki S., Yasaka M., Takaki Y., Matsui T., Tanabe H., Iwashita A., Ota A. Usefulness of magnifying endoscopy with narrow-band imaging for determining the horizontal extent of early gastric cancer when there is an unclear margin by chrmoendoscopy (with video) Gastrointest. Endosc. 2011;74:1259–1267. doi: 10.1016/j.gie.2011.09.005. - DOI - PubMed
    1. Inoue H., Sasajima K., Kaga M., Sugaya S., Sato Y., Wada Y., Inui M., Satodate H., Kudo S.E., Kimura S., et al. Endoscopic in vivo evaluation of tissue atypia in the esophagus using a newly designed integrated endocytoscope: A pilot trial. Endoscopy. 2006;38:891–895. doi: 10.1055/s-2006-944667. - DOI - PubMed
    1. Kumagai Y., Kawada K., Yamazaki S., Iida M., Momma K., Odajima H., Kawachi H., Nemoto T., Kawano T., Takubo K. Endocytoscopic observation for esophageal squamous cell carcinoma: Can biopsy histology be omitted? Dis. Esophagus. 2009;22:505–512. doi: 10.1111/j.1442-2050.2009.00952.x. - DOI - PubMed